Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

BACKGROUND: The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mutations in the BRAF gene, inhibitors designed speci...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Crespo-Rodriguez, Eva, Bergerhoff, Katharina, Bozhanova, Galabina, Foo, Shane, Patin, Emmanuel C, Whittock, Harriet, Buus, Richard, Haider, Syed, Muirhead, Gareth, Thway, Khin, Newbold, Kate, Coffin, Robert S, Vile, Richard G, Kim, Dae, McLaughlin, Martin, Melcher, Alan A, Harrington, Kevin J, Pedersen, Malin
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Oncolytic and Local Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7445339/
https://ncbi.nlm.nih.gov/pubmed/32759235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000698
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados